Foundayo is approved, but price and stock still matter more than the headline.
The UK has authorised a second weight-loss pill. For patients, the useful question is not just whether it exists, but when it can be prescribed, what it costs and how it compares with Wegovy and Mounjaro.
The biggest UK weight-loss story this week was the MHRA authorising orforglipron, branded Foundayo. It gives patients another tablet option alongside oral Wegovy, and it puts pressure on private providers to explain the real monthly cost rather than just open pre-order lists.
At the same time, a third oral GLP-1 candidate, aleniglipron, published phase 2 results and moved into phase 3. The direction of travel is clear: weight-loss treatment is no longer only an injection market. But for anyone choosing treatment today, availability, prescribing checks and dose-by-dose pricing still matter more than launch noise.
In this round-up
The UK becomes the first country in Europe to approve Foundayo
On 10 August, the MHRA authorised orforglipron, sold as Foundayo, for weight management and type 2 diabetes. It is Eli Lilly's oral GLP-1 medicine, and the UK approval came ahead of wider European availability.
The licence covers adults with a BMI of 30 or above, or a BMI from 27 to 30 with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. The practical difference from oral Wegovy is routine: Foundayo is taken once a day, at any time, without food and water timing rules.
Trial evidence published in the New England Journal of Medicine reported average weight loss up to 11.2% over 72 weeks at the highest dose, compared with 2.1% on placebo. That sits below the headline results people associate with injectable Mounjaro, so the pitch is convenience rather than maximum potency.
If injections have put you off treatment, Foundayo is worth watching. But approval is not the same as NHS funding or immediate supply. Private access is likely to move first, and NICE's November decision is the important date for anyone hoping the NHS will pay.
A third weight-loss pill has posted phase 2 results
While Foundayo took the headlines, Structure Therapeutics published phase 2 results for aleniglipron, another once-daily oral GLP-1 candidate. In the study, the highest dose produced average weight loss of 12.1% over 36 weeks, compared with 0.5% on placebo.
The trial involved 230 adults across 38 US medical centres. Reported side effects were mostly gastrointestinal, as expected for this medicine class, and around 10% of participants stopped treatment during the study.
The reason this matters for UK patients is not immediate access. It is competition. Small-molecule oral GLP-1 medicines should be easier to manufacture at scale than injectable peptide medicines, which is one reason prices could eventually become more competitive.
Aleniglipron will not change your choices this month. It is still years from routine UK prescribing if it succeeds. What it does signal is that today's oral GLP-1 prices are unlikely to be the final market shape, so be cautious about long commitments that make switching difficult.
Approved but not in stock: how to read Foundayo pre-order pages
Several UK providers opened Foundayo sign-up or pre-order pages quickly after the approval. That can be legitimate, but it does not mean the medicine is ready to dispatch or that the final price is confirmed.
Eli Lilly has not confirmed a UK private price publicly. Some provider pages are publishing indicative ranges, but those should be treated as estimates until real dose-by-dose pricing is live. The same caution applies to any site claiming immediate dispatch before stock is actually released.
| Treatment | Current patient reality | What to check |
|---|---|---|
| Foundayo | Approved, with pre-orders appearing | Confirmed launch date, dose prices and consultation checks |
| Oral Wegovy | Already available privately through some providers | Starter dose versus maintenance dose pricing |
| Mounjaro | Widely available privately as an injection | Higher-dose cost and ongoing clinical support |
Do not pay upfront for an unconfirmed price. Wait for providers to publish real monthly costs, then compare properly against Wegovy, Mounjaro and the wider weight-loss provider market. A regulated provider should still check your height, weight and BMI before prescribing.
Safety checks are becoming part of the comparison
- Independent BMI checks: online pharmacies are expected to verify height, weight and BMI rather than relying only on a questionnaire.
- Counterfeit risk: tablets are easier to fake than injector pens, so avoid any site offering instant supply with no consultation.
- Pricing clarity: oral GLP-1 providers should show the dose ladder, not just the cheapest starter month.
Beyond weight loss: hair loss, ED, TRT and blood testing
- Erectile dysfunction: generic sildenafil remains one of the cheapest private treatment categories, so compare per-tablet cost rather than branding.
- Hair loss: finasteride prescribing should still include clear warnings about sexual side effects and mood changes before treatment starts.
- Blood tests: the market is moving beyond basic finger-prick kits, with more venous and assisted collection options appearing for patients who need better sample reliability.
- TRT: a proper testosterone diagnosis needs symptoms plus confirmed low morning testosterone readings, so avoid clinics that skip confirmatory testing.
Medical disclaimer
This article is for general information only and is not medical advice. Weight-loss medicines are prescription treatments and should only be used after assessment by a qualified healthcare professional.
